Deuterium Metabolic Imaging: Exploring Metabolic Insights in a Rat Glioma Model: in vitro and in vivo

Summarise with VIRAT
Authors: W. Shi, L. Kuebler, R. Pohmann, Praveen Iyyappan Valsala, N. Avdievitch, K. Scheffler, A. Martins
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: Gliomas are metabolically heterogeneous brain tumors characterized by altered glycolytic metabolism. Mutations in IDH profoundly reprogram glioma metabolism, producing distinct oxidative metabolic profiles. Quantitative, non-invasive assessment of these metabolic phenotypes is essential for understanding subtype-specific cancer biology. Deuterium metabolic imaging (DMI) provides spatially resolved, quantitative insights into glucose metabolism. Here, we used DMI to quantify glycolytic activity in U-87 (IDH–wildtype) and IDH-mutant glioma mouse models, revealing distinct metabolic phenotypes. Methods: Glycolytic activity was quantified in vitro using the Seahorse XF Glycolytic Rate Assay by measuring the proton efflux rate (PER). Sequential injections of Rot/AA and 2-DG distinguished mitochondrial from glycolytic acidification, and values were normalized to cell number count. Lactate secretion from U-87 and IDH-mutant glioma cells was measured after 24 h and 48 h using a colorimetric assay. Cells incubated with [6,6′-²H₂]glucose were analyzed by DMI spectroscopy at 1, 3, 5, and 7 h on a 7 T Bruker Biospec system, and deuterated glucose and lactate were quantified. For in vivo DMI, rats bearing U-87 (n = 6–7) or IDH-mutant (n = 4) gliomas were scanned dynamically after injection of [6,6′-²H₂]glucose(Fig. 2A). The AMARES method was applied to generate quantitative maps of metabolites. Results/Discussion: Seahorse analysis showed that both basal and compensatory glycolysis were lower in U-87 cells than in IDH-mutant cells, indicating reduced real-time glycolytic flux and proton release. Conversely, lactate assays revealed greater lactate accumulation in U-87 cultures at 24 h& 48 h, suggesting delayed export or sustained lactate buildup over time, rather than increased instant glycolytic activity. We established a quantitative DMI setup validated with [6,6′-²H₂]glucose and [²H₂]L-lactate phantoms. In vitro DMI demonstrated that IDH-mutant cells generated lactate more rapidly during the first hour, whereas U-87 cells reached higher levels at later time points, consistent with slower but sustained glycolytic flux. In vivo DMI revealed progressive glucose depletion in U-87 tumors, with larger lesions showing lower glucose levels, suggesting a higher metabolic demand. IDH tumors initially exhibited lower glucose levels but showed a transient rise later, indicating possible glycogenolysis. Conclusion: We developed a 7T DMI method that enables the quantitative mapping of glycolytic phenotypes both in vitro and in vivo. IDH-mutant cells displayed rapid glucose-to-lactate conversion, while U-87 cells showed slower but sustained lactate accumulation. In vivo, DMI captured progressive glucose depletion in U-87 and transient glucose rebound in IDH-mutant tumors, demonstrating its power to quantify tumor metabolic heterogeneity.

Fields of Study & Subjects

Metabolomics and Mass Spectrometry Studies Glioma Diagnosis and Treatment Cancer Hypoxia and Metabolism

Publication details

Journal / source
MPG.PuRe (Max Planck Society)
Publication date
1 January 2026
Language
EN